Neuberger Berman Group LLC Trims Holdings in Zimmer Biomet Holdings Inc (ZBH)

Neuberger Berman Group LLC lessened its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 8.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,348,242 shares of the medical equipment provider’s stock after selling 132,225 shares during the period. Neuberger Berman Group LLC owned approximately 0.67% of Zimmer Biomet worth $157,866,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in ZBH. Bessemer Group Inc. grew its stake in Zimmer Biomet by 21.1% in the second quarter. Bessemer Group Inc. now owns 4,297 shares of the medical equipment provider’s stock valued at $552,000 after acquiring an additional 750 shares during the period. IFP Advisors Inc grew its stake in Zimmer Biomet by 22.4% in the second quarter. IFP Advisors Inc now owns 2,077 shares of the medical equipment provider’s stock valued at $267,000 after acquiring an additional 380 shares during the period. Global X Management Co. LLC grew its stake in Zimmer Biomet by 41.6% in the second quarter. Global X Management Co. LLC now owns 6,315 shares of the medical equipment provider’s stock valued at $811,000 after acquiring an additional 1,854 shares during the period. Trexquant Investment LP acquired a new stake in Zimmer Biomet in the second quarter valued at approximately $231,000. Finally, Canada Pension Plan Investment Board grew its stake in Zimmer Biomet by 7.7% in the second quarter. Canada Pension Plan Investment Board now owns 51,861 shares of the medical equipment provider’s stock valued at $6,659,000 after acquiring an additional 3,700 shares during the period. 86.24% of the stock is owned by hedge funds and other institutional investors.

ZBH has been the subject of a number of research reports. SunTrust Banks set a $136.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a research note on Wednesday, November 1st. Royal Bank of Canada dropped their target price on Zimmer Biomet to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, November 7th. Morgan Stanley dropped their target price on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a report on Thursday, November 2nd. BMO Capital Markets dropped their target price on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating on the stock in a report on Thursday, November 2nd. Finally, Deutsche Bank upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 target price on the stock in a report on Tuesday, November 14th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $134.05.

Shares of Zimmer Biomet Holdings Inc (ZBH) traded down $0.02 during trading on Thursday, reaching $113.52. The company had a trading volume of 2,815,500 shares, compared to its average volume of 1,362,485. The company has a market capitalization of $22,988.79, a price-to-earnings ratio of 14.07, a P/E/G ratio of 1.76 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 1-year low of $100.81 and a 1-year high of $133.49. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The business’s revenue was down .8% compared to the same quarter last year. During the same quarter last year, the business posted $1.79 earnings per share. research analysts anticipate that Zimmer Biomet Holdings Inc will post 8.03 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Neuberger Berman Group LLC Trims Holdings in Zimmer Biomet Holdings Inc (ZBH)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://ledgergazette.com/2017/12/14/neuberger-berman-group-llc-trims-holdings-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply